These LOX-1+ cells were polymorphonuclear myeloid-derived suppressor cells with immunosuppressive properties (repression of T-cell response ascertained by reduced IFN-γ production); they peaked some days (3 to 9 days) after intensive care unit admission and significantly increased within the first three days in COVID-19 patients who developed ARDS within this time frame [35]. The gene discussed is OLR1; the disease is COVID-19.